GoldenBiotech Received FDA AoR of its Pre-EUA Meeting Request for COVID-19 Trial Drug Antroquinonol

FDA Approves GoldenBiotech’s IND Application of Antroquinonol for Phase II Trial on Relapsed Acute Myeloid Leukemia (AML)

GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Patients

COVID-19 Scoop: Epoch-Making GoldenBiotech’s Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

國鼎生技與奧地利Sanova Pharma 簽署新冠肺炎新藥在歐洲23國的合作備忘錄

GoldenBiotech Antroquinonol Granted Compassionate Use in Taiwan for Treating Covid-19 Patients

Covid-19 Trial: GoldenBiotech New Drug Antroquinonol Passed 2nd DMC Review in the USA

國鼎生技血癌二期臨床結果論文摘要榮獲ASCO審查通過於大會官網發表

GoldenBiotech Completes Second Interim of Patients Enrollment for Covid-19 Phase 2 Clinical Trial

GoldenBiotech Presents Outstanding Results of Potential Treatment for Relapsed AML in ASCO 2021

國鼎生技收到BNC Korea Co., Ltd.依約支付新冠肺炎(Covid-19)新藥授權之第二期簽約金200萬美元

Covid-19 Drug Duo Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries